Intact Vascular Hires Chief Executive

Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, hired Bruce J. Shook as president and CEO. Shook also will join the company’s board. He spent the past 11 years at Neuronetics, a medical device company he co-founded in 2003 and led as president and CEO. Neuronetics develops neuromodulation products for psychiatric and neurologic diseases.

“We are delighted to have Bruce at the helm,” said Dennis Wahr, board chairman. “His wealth of successful operational experience in medical device companies is a prerequisite to expedite Intact’s growth to the next level of both product and clinical development.”

Prior to Neuronetics, Shook co-founded Neuron Therapeutics, a privately held company developing drug/device combination products for the treatment of traumatic central nervous system disorders. Prior to Neuron Therapeutics, Shook was president of Abiomed, a publicly traded manufacturer of advanced cardiac assist technology, where he worked to bring the first ventricular assist device to the U.S. market and was responsible for all commercial operations. He has also held positions in engineering, clinical research and regulatory affairs with Cordis Corporation. Mr. Shook has 30 years of experience in the medical device industry including venture finance of early stage companies.

“I am very impressed with what the Intact Vascular team has accomplished,” Shook said. “They have developed an extraordinarily innovative approach to the treatment of peripheral vascular disease that holds significant promise to advance endovascular therapy beyond the current practice of stenting. Intact has exceptional assets and I am truly excited to be working with this team to improve patient care, offer customers novel solutions, and build value for our stakeholders.”

Shook holds advanced degrees in biomedical engineering and business administration from Columbia University and the MIT Sloan School of Management, respectively, and a bachelor’s degree in chemical engineering from Penn State University.

Wayne, Pa.-based Intact Vascular’s primary product, the Tack-It Endovascular System, is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology, according to company officials, will offer physicians a new treatment option for treating peripheral artery disease. The product has not yet been approved by the U.S. Food and Drug Administration. The company was founded in 2011.